相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
Thomas H. Pillow et al.
CHEMMEDCHEM (2020)
Structure-Based Design of a Macrocyclic PROTAC
Andrea Testa et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
Optical Control of Small Molecule-Induced Protein Degradation
Yuta Naro et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2020)
PHOTACs enable optical control of protein degradation
Martin Reynders et al.
SCIENCE ADVANCES (2020)
Emerging roles of and therapeutic strategies targeting BRD4 in cancer
Mary E. White et al.
CELLULAR IMMUNOLOGY (2019)
Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
Yonghui Sun et al.
LEUKEMIA (2019)
The BAF complex in development and disease
Amelie Alfert et al.
EPIGENETICS & CHROMATIN (2019)
From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1)
James W. Papatzimas et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
Lu Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation
George M. Burslem et al.
CANCER RESEARCH (2019)
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
William Farnaby et al.
NATURE CHEMICAL BIOLOGY (2019)
Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment
Keiko Yamakawa et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands
Ziqian Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Development of targeted protein degradation therapeutics
Philip P. Chamberlain et al.
NATURE CHEMICAL BIOLOGY (2019)
Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs
Patrick Pfaff et al.
ACS CENTRAL SCIENCE (2019)
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
Longchuan Bai et al.
CANCER CELL (2019)
BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation
Drishti Rathod et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Light-Induced Protein Degradation with Photocaged PROTACs
Gang Xue et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2019)
Targeted protein degradation: expanding the toolbox
Matthieu Schapira et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis
Chengcheng Shi et al.
CELL DEATH & DISEASE (2019)
MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
John Hines et al.
CANCER RESEARCH (2019)
Very low intensity ultrasounds as a new strategy to improve selective delivery of nanoparticles-complexes in cancer cells
Rossella Loria et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein
Haibin Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Developing potent PROTACs tools for selective degradation of HDAC6 protein
Zixuan An et al.
PROTEIN & CELL (2019)
PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding
Christopher P. Tinworth et al.
ACS CHEMICAL BIOLOGY (2019)
Targeting transcription factors in cancer - from undruggable to reality
John H. Bushweller
NATURE REVIEWS CANCER (2019)
Targeted inhibition of STAT3 as a potential treatment strategy for atherosclerosis
Qi Chen et al.
THERANOSTICS (2019)
ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer
J. J. Flanagan et al.
CANCER RESEARCH (2019)
A Click Chemistry Platform for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation
Ryan P. Wurz et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
Bing Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation
Alexandru D. Buhimschi et al.
BIOCHEMISTRY (2018)
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
Yonghui Sun et al.
CELL RESEARCH (2018)
STAT3, stem cells, cancer stem cells and p63
Michaela Galoczova et al.
CELLULAR & MOLECULAR BIOLOGY LETTERS (2018)
Design and Synthesis of Novel Bispecific Molecules for Inducing BRD4 Protein Degradation
Wang Shihui et al.
CHEMICAL RESEARCH IN CHINESE UNIVERSITIES (2018)
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
Chong Qin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma
Xiaohui Zhang et al.
LEUKEMIA (2018)
Delineating the role of cooperativity in the design of potent PROTACs for BTK
Adelajda Zorba et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
ARV-110: An androgen receptor PROTAC degrader for prostate cancer
Taavi Neklesa et al.
CANCER RESEARCH (2018)
STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis
Stephen D'Amico et al.
GENES & DEVELOPMENT (2018)
FLT3 inhibitors in acute myeloid leukemia
Mei Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion
George M. Burslem et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
Hai-Tsang Huang et al.
CELL CHEMICAL BIOLOGY (2018)
Development of Stabilized Peptide-Based PROTACs against Estrogen Receptor alpha
Yanhong Jiang et al.
ACS CHEMICAL BIOLOGY (2018)
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Cornerstones of CRISPR-Cas in drug discovery and therapy
Christof Fellmann et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)
Nobumichi Ohoka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
D. T. Saenz et al.
LEUKEMIA (2017)
BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment
Georg E. Winter et al.
MOLECULAR CELL (2017)
FDA-Approved Oligonucleotide Therapies in 2017
Cy A. Stein et al.
MOLECULAR THERAPY (2017)
Structural basis of PROTAC cooperative recognition for selective protein degradation
Morgan S. Gadd et al.
NATURE CHEMICAL BIOLOGY (2017)
Delivery technologies for genome editing
Hao Yin et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Waste disposal-An attractive strategy for cancer therapy
Jemilat Salami et al.
SCIENCE (2017)
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors
Bao Nguyen et al.
ONCOTARGET (2017)
Hydrophobic tagging-mediated degradation of Alzheimer's disease related Tau
Na Gao et al.
RSC ADVANCES (2017)
Immunomodulatory Effect of Flavonoids of Blueberry (Vaccinium corymbosum L.) Leaves via the NF-κB Signal Pathway in LPS-Stimulated RAW 264.7 Cells
Dazhi Shi et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2017)
Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation
Philipp Ottis et al.
ACS CHEMICAL BIOLOGY (2017)
Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands
Norihito Shibata et al.
CANCER SCIENCE (2017)
Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)
Caroline M. Robb et al.
CHEMICAL COMMUNICATIONS (2017)
Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
Longchuan Bai et al.
CANCER RESEARCH (2017)
Transcriptional Addiction in Cancer
James E. Bradner et al.
CELL (2017)
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL
Ashton C. Lai et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand
Yosuke Demizu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
Nobumichi Ohoka et al.
CURRENT CANCER DRUG TARGETS (2016)
Ubiquilin-mediated Small Molecule Inhibition of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling
Rory T. Coffey et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Kanak Raina et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
Honorine Lebraud et al.
ACS CENTRAL SCIENCE (2016)
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Michael Zengerle et al.
ACS CHEMICAL BIOLOGY (2015)
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Jing Lu et al.
CHEMISTRY & BIOLOGY (2015)
Oligonucleotide Therapies: The Past and the Present
Karin E. Lundin et al.
HUMAN GENE THERAPY (2015)
Knocking down disease: a progress report on siRNA therapeutics
Anders Wittrup et al.
NATURE REVIEWS GENETICS (2015)
Phthalimide conjugation as a strategy for in vivo target protein degradation
Georg E. Winter et al.
SCIENCE (2015)
B-Cell Receptor Signaling in Diffuse Large B-Cell lymphoma
Ryan M. Young et al.
SEMINARS IN HEMATOLOGY (2015)
Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance
Manuel Buscarlet et al.
BLOOD (2014)
Structure of the DDBI-CRBN E3 ubiquitin ligase in complex with thalidomide
Eric S. Fischer et al.
NATURE (2014)
Regulation of STAT signaling by acetylation
Shougang Zhuang
CELLULAR SIGNALLING (2013)
Inhibitor of Apoptosis (IAP) Proteins-Modulators of Cell Death and Inflammation
John Silke et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
Inhibitor Mediated Protein Degradation
Marcus J. C. Long et al.
CHEMISTRY & BIOLOGY (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia
Oliver Hantschel et al.
NATURE CHEMICAL BIOLOGY (2012)
Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins
Taavi K. Neklesa et al.
NATURE CHEMICAL BIOLOGY (2011)
Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells
Ellen Weisberg et al.
PLOS ONE (2011)
Mcl-1; the molecular regulation of protein function
Luke W. Thomas et al.
FEBS LETTERS (2010)
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer
Angelo Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain
Abdalla J. Mohamed et al.
IMMUNOLOGICAL REVIEWS (2009)
Quality Control Against Misfolded Proteins in the Cytosol: A Network for Cell Survival
Hiroshi Kubota
JOURNAL OF BIOCHEMISTRY (2009)
Inhibitors of the MDM2-p53 interaction as anticancer drugs
Ian R. Hardcastle
DRUGS OF THE FUTURE (2007)
Structural basis for an unexpected mode of SERM-mediated ER antagonism
YL Wu et al.
MOLECULAR CELL (2005)
Expression profiling reveals off-target gene regulation by RNAi
AL Jackson et al.
NATURE BIOTECHNOLOGY (2003)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways
M Mizuki et al.
BLOOD (2000)
分享论文
